liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor
Stanford University, CA 94305 USA.
Stanford University, CA 94305 USA.
Stanford University, CA 94305 USA.
Stanford University, CA 94305 USA.
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 8, nr 32, s. 52345-52356Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Chemoresistant cancer cells express high levels of aldehyde dehydrogenases (ALDHs), particularly in head and neck squamous cell carcinoma (HNSCC). The ALDH family of enzymes detoxify both exogenous and endogenous aldehydes. Since many chemotherapeutic agents, such as cisplatin, result in the generation of cytotoxic aldehydes and oxidative stress, we hypothesized that cells expressing high levels of ALDH may be more chemoresistant due to their increased detoxifying capacity and that inhibitors of ALDHs may sensitize them to these drugs. Here, we show that overall ALDH activity is increased with cisplatin treatment of HNSCC and that ALDH3A1 protein expression is particularly enriched in cells treated with cisplatin. Activation of ALDH3A1 by a small molecule activator (Alda-89) increased survival of HNSCC cells treated with cisplatin. Conversely, treatment with a novel small molecule ALDH inhibitor (Aldi-6) resulted in a marked decrease in cell viability, and the combination of Aldi-6 and cisplatin resulted in a more pronounced reduction of cell viability and a greater reduction in tumor burden in vivo than what was observed with cisplatin alone. These data indicate that ALDH3A1 contributes to cisplatin resistance in HNSCC and that the targeting of ALDH, specifically, ALDH3A1, appears to be a promising strategy in this disease.

Ort, förlag, år, upplaga, sidor
IMPACT JOURNALS LLC , 2017. Vol. 8, nr 32, s. 52345-52356
Nyckelord [en]
aldehyde dehydrogenase; chemoresistance; head and neck squamous cell carcinoma; small molecule inhibitors
Nationell ämneskategori
Cell- och molekylärbiologi
Identifikatorer
URN: urn:nbn:se:liu:diva-140048DOI: 10.18632/oncotarget.17017ISI: 000407124100027OAI: oai:DiVA.org:liu-140048DiVA, id: diva2:1136612
Anmärkning

Funding Agencies|NIH [DE024402, NIAAA11147, T32 CA09151]; Developmental Cancer Research Grant for Translational Medicine from the Stanford Cancer Institute

Tillgänglig från: 2017-08-28 Skapad: 2017-08-28 Senast uppdaterad: 2018-01-13

Open Access i DiVA

fulltext(1960 kB)85 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1960 kBChecksumma SHA-512
6a74cf95711168f0576dbe19ef2738a589cd349c9d2e1e059f72f2dfbaae04451c9d9f5fb6dc0ce073a9d9e7ead4170428819765ce9363f3a42ec62518971449
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltext

Sök vidare i DiVA

Av författaren/redaktören
Farnebo, Lovisa
Av organisationen
Avdelningen för Logopedi, Audiologi och OtorhinolaryngologiMedicinska fakultetenÖron- näsa- och halskliniken US
I samma tidskrift
OncoTarget
Cell- och molekylärbiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 85 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 235 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf